Pfizer's Covid-19 vaccine safe and 95% effective, find final study results

The coronavirus vaccine developed by Pfizer has shown 95 per cent efficacy in the late-stage trial, the company said on Wednesday. The drugmaker said the efficacy of the vaccine developed with German partner BioNTech SE was consistent across age and ethnicity demographics, and that there were no major side effects, a sign that the immunization could be employed broadly around the world. Efficacy in adults over 65 years, who are at particular risk from the virus, was over 94 per cent. The pharmaceutical giant said that it plans to apply for emergency US authorisation within days. The final analysis comes just one week after initial results from the trial showed the vaccine was more than 90 per cent effective. Moderna Inc on Monday released preliminary data for its vaccine, showing similar effectiveness.